Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + aspirin + ramipril
- Development stage
- Phase 3
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pleopill is a cardiovascular fixed-dose combination (polypill) developed and marketed by Zinnia Life Sciences. It contains three active pharmaceutical ingredients: **atorvastatin**, an HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol; **aspirin**, a salicylate that acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1); and **ramipril**, an angiotensin-converting enzyme (ACE) inhibitor used to manage hypertension and reduce the risk of heart failure. Pleopill is primarily indicated for the secondary prevention of major adverse cardiovascular events (MACE), such as myocardial infarction and stroke, in patients with established cardiovascular disease or multiple risk factors. The use of a polypill is intended to simplify complex medication regimens and improve long-term patient adherence.
- Brand names
- Pleopill
- Other names
- Atorvastatin/Aspirin/Ramipril combination
02
Targets
ACE (Angiotensin Converting Enzyme)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + aspirin + ramipril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + aspirin + ramipril.